The Proceedings of the American Thoracic Society 3:680-686 (2006)
© 2006 The American Thoracic Society doi: 10.1513/pats.200605-118SF
Pulmonary Hypertension Due to BMPR2 Mutation
A New Paradigm for Tissue Remodeling?
Nicholas W. Morrell
Division of Respiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Correspondence and requests for reprints should be addressed to Nicholas W. Morrell, M.A., M.D., F.R.C.P., Department of Medicine, University of Cambridge, Box 157, Level 5, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK. E-mail: nwm23{at}cam.ac.uk
ABSTRACT
Genetic studies in familial pulmonary arterial hypertension (FPAH) have revealed heterozygous germline mutations in the bone morphogenetic protein type II receptor (BMPR-II), a receptor for the transforming growth factor (TGF)-ß/bone morphogenetic protein (BMP) superfamily. PAH is characterized by intense remodeling of small pulmonary arteries by myofibroblast and smooth muscle proliferation. BMPR-II mutation in pulmonary artery smooth muscle cells contributes to abnormal growth responses to BMPs and TGF-ß. Reduced expression or function of BMPR-II signaling leads to exaggerated TGF-ß signaling and altered cellular responses to TGF-ß. The likely mechanism involves an interaction between BMP and TGF-ßregulated Smad pathways. In endothelial cells, BMPR-II mutation increases the susceptibility of cells to apoptosis. The combination of increased endothelial apoptosis and failure of growth suppression in pulmonary artery smooth muscle cells provides important clues to the cellular pathogenesis of PAH. The reciprocal regulation of TGF-ß and BMP signaling in models of tissue repair may provide new approaches to our understanding of lung disease.
Key Words: genetics pulmonary arterial hypertension transforming growth factor-ß
This article has been cited by other articles:

|
 |

|
 |
 
E. D. Austin, J. D. Cogan, J. D. West, L. K. Hedges, R. Hamid, E. P. Dawson, L. A. Wheeler, F. F. Parl, J. E. Loyd, and J. A. Phillips III
Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females
Eur. Respir. J.,
November 1, 2009;
34(5):
1093 - 1099.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Hall, P Brogan, S G Haworth, and N Klein
Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children
Thorax,
September 1, 2009;
64(9):
778 - 783.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Huang, D. Wang, K. Ihida-Stansbury, P. L. Jones, and J. F. Martin
Defective pulmonary vascular remodeling in Smad8 mutant mice
Hum. Mol. Genet.,
August 1, 2009;
18(15):
2791 - 2801.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Hamid and J. H. Newman
Evidence for Inflammatory Signaling in Idiopathic Pulmonary Artery Hypertension: TRPC6 and Nuclear Factor-{kappa}B
Circulation,
May 5, 2009;
119(17):
2297 - 2298.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. N. Davis, A. C. Hilyard, P. H. Nguyen, G. Lagna, and A. Hata
Induction of MicroRNA-221 by Platelet-derived Growth Factor Signaling Is Critical for Modulation of Vascular Smooth Muscle Phenotype
J. Biol. Chem.,
February 6, 2009;
284(6):
3728 - 3738.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Long, A. Crosby, X. Yang, M. Southwood, P. D. Upton, D.-K. Kim, and N. W. Morrell
Altered Bone Morphogenetic Protein and Transforming Growth Factor-{beta} Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease
Circulation,
February 3, 2009;
119(4):
566 - 576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Sevilla-Perez, M. Konigshoff, G. Kwapiszewska, O. V. Amarie, W. Seeger, N. Weissmann, R. T. Schermuly, R. E. Morty, and O. Eickelberg
Shroom expression is attenuated in pulmonary arterial hypertension
Eur. Respir. J.,
October 1, 2008;
32(4):
871 - 880.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Moreno-Vinasco, M. Gomberg-Maitland, M. L. Maitland, A. A. Desai, P. A. Singleton, S. Sammani, L. Sam, Y. Liu, A. N. Husain, R. M. Lang, et al.
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension
Physiol Genomics,
April 1, 2008;
33(2):
278 - 291.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Newman, J. A. Phillips III, and J. E. Loyd
Narrative Review: The Enigma of Pulmonary Arterial Hypertension: New Insights from Genetic Studies
Ann Intern Med,
February 19, 2008;
148(4):
278 - 283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. B. Yu, D. Y. Deng, H. Beppu, C. C. Hong, C. Lai, S. A. Hoyng, N. Kawai, and K. D. Bloch
Bone Morphogenetic Protein (BMP) Type II Receptor Is Required for BMP-mediated Growth Arrest and Differentiation in Pulmonary Artery Smooth Muscle Cells
J. Biol. Chem.,
February 15, 2008;
283(7):
3877 - 3888.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. B. Sehgal and S. Mukhopadhyay
Dysfunctional Intracellular Trafficking in the Pathobiology of Pulmonary Arterial Hypertension
Am. J. Respir. Cell Mol. Biol.,
July 1, 2007;
37(1):
31 - 37.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. B. Sehgal and S. Mukhopadhyay
Pulmonary arterial hypertension: a disease of tethers, SNAREs and SNAPs?
Am J Physiol Heart Circ Physiol,
July 1, 2007;
293(1):
H77 - H85.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 by the American Thoracic Society.
|
|
|